Floatz logo

ct103a cells

Neuromyelitis Optica Spectrum Disorder

Tongji HospitalCell therapyEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
89/ 100

Competitive context

18 Active assets in the Neuromyelitis Optica Spectrum Disorder cohort.

Asset / SponsorPhaseRating
CARMUSTINE
Fred Hutchinson Cancer Center
Phase 2CCC
Cytosin-Arabinosid
Fred Hutchinson Cancer Center
Phase 2CCC
Anti-Thymoglobulin, Rabbit
Fred Hutchinson Cancer Center
Phase 2CCC
ETOPOSIDE
Fred Hutchinson Cancer Center
Phase 2CCC
PREDNISONE TABLETS
Fred Hutchinson Cancer Center
Phase 2CCC

View all 20 →

Same molecule, other indications

ct103a cells is also rated in:

idiopathic inflammatory myopathyDormant
C
Indicative ·
39 / 100
View asset →
chronic inflammatory demyelinating polyradiculoneuropathyDormant
C
Indicative ·
39 / 100
View asset →
autoimmune encephalitisDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →